Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Invasive ductal carcinoma with in situ pattern: how to avoid this diagnostic pitfall?

Mohan N, Black JO, Schwartz MR, Zhai QJ.

Am J Transl Res. 2016 Aug 15;8(8):3337-41. eCollection 2016.

2.

Novel Use for DOG1 in Discriminating Breast Invasive Carcinoma from Noninvasive Breast Lesions.

Cheng H, Yang S, Qu Z, Zhou S, Ruan Q.

Dis Markers. 2016;2016:5628176. doi: 10.1155/2016/5628176. Epub 2016 Mar 2.

3.

Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.

Russell TD, Jindal S, Agunbiade S, Gao D, Troxell M, Borges VF, Schedin P.

Am J Pathol. 2015 Nov;185(11):3076-89. doi: 10.1016/j.ajpath.2015.07.004. Epub 2015 Sep 4.

4.

Lattice-based model of ductal carcinoma in situ suggests rules for breast cancer progression to an invasive state.

Boghaert E, Radisky DC, Nelson CM.

PLoS Comput Biol. 2014 Dec 4;10(12):e1003997. doi: 10.1371/journal.pcbi.1003997. eCollection 2014 Dec.

5.

Significance of immunohistochemistry in breast cancer.

Zaha DC.

World J Clin Oncol. 2014 Aug 10;5(3):382-92. doi: 10.5306/wjco.v5.i3.382. Review.

6.

Adenoma of the nipple: A clinicopathological report of 13 cases.

DI Bonito M, Cantile M, Collina F, D'Aiuto M, Liguori G, DE Cecio R, Botti G.

Oncol Lett. 2014 Jun;7(6):1839-1842. Epub 2014 Mar 28.

7.

p40 (ΔNp63) expression in breast disease and its correlation with p63 immunohistochemistry.

Kim SK, Jung WH, Koo JS.

Int J Clin Exp Pathol. 2014 Feb 15;7(3):1032-41. eCollection 2014.

8.

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.

Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M.

Breast Cancer Res Treat. 2013 Nov;142(1):69-80.

9.
10.

Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma.

Hua X, Yu L, Huang X, Liao Z, Xian Q.

Diagn Pathol. 2011 Nov 8;6:111. doi: 10.1186/1746-1596-6-111.

11.
12.

The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung.

Conde E, Angulo B, Redondo P, Toldos O, García-García E, Suárez-Gauthier A, Rubio-Viqueira B, Marrón C, García-Luján R, Sánchez-Céspedes M, López-Encuentra A, Paz-Ares L, López-Ríos F.

PLoS One. 2010 Aug 17;5(8):e12209. doi: 10.1371/journal.pone.0012209.

13.
14.

A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers.

Zhang RR, Man YG, Vang R, Saenger JS, Barner R, Wheeler DT, Liang CY, Vinh TN, Bratthauer GL.

Breast Cancer Res. 2003;5(5):R151-6. Epub 2003 Jul 24.

15.

Supplemental Content

Support Center